New combo aims to boost radiation therapy for neuroendocrine tumors
NCT ID NCT05724108
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 4 times
Summary
This phase II trial tests whether adding the drug triapine to standard radioactive therapy (lutetium Lu 177 dotatate) helps shrink or slow the growth of metastatic neuroendocrine tumors. About 94 adults with well-differentiated, somatostatin receptor-positive tumors will be randomly assigned to get the combo or the standard therapy alone. The goal is to see if the combination leads to more tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- triapine and lutetium Lu 177 dotatate
- What this could lead to
- If it works, this combination could shrink tumors or slow their growth better than the current standard therapy for people with metastatic neuroendocrine tumors.
- What could go wrong
- This is a mid-stage trial with only 94 participants, so results may not apply to everyone. Adding triapine could also increase side effects without improving outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112, United States
-
NYP/Weill Cornell Medical Center
New York, New York, 10065, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California, 92612, United States
-
UF Health Cancer Institute - Gainesville
Gainesville, Florida, 32610, United States
-
UM Sylvester Comprehensive Cancer Center at Aventura
Aventura, Florida, 33180, United States
-
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida, 33146, United States
-
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida, 33442, United States
-
UM Sylvester Comprehensive Cancer Center at Kendall
Miami, Florida, 33176, United States
-
UM Sylvester Comprehensive Cancer Center at Plantation
Plantation, Florida, 33324, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
UT MD Anderson - League City
League City, Texas, 77573, United States
-
UT MD Anderson - Sugar Land
Sugar Land, Texas, 77478, United States
-
UT MD Anderson - The Woodlands
Conroe, Texas, 77384, United States
-
UT MD Anderson - West Houston
Houston, Texas, 77079, United States
-
UT MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, 40536, United States
-
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, 33136, United States
-
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Madison, Wisconsin, 53718, United States
-
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, 53792, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.